Filed Pursuant to Rule 424(b)(5)
Registration No. 333-275376
PROSPECTUS SUPPLEMENT
(To Prospectus Supplement dated
March 22, 2024 and Prospectus dated March 22, 2024)
Up to $7,000,000
Common Stock
This prospectus supplement
amends and supplements the information in the prospectus supplement, dated March 22, 2024 (the “Prior Prospectus Supplement”), filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-275376), relating to the offer and sale of up to $3,100,000 of shares of our common stock, $0.01 par value per share, pursuant to the Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”), dated March 8, 2024, we previously entered into with Cantor Fitzgerald & Co. and A.G.P./Alliance Global Partners (each an
“Agent” and together, the “Agents”). This prospectus supplement is registering the offer and sales of up to $7,000,000 of shares of our common stock. This prospectus supplement should be read in conjunction with the Prior
Prospectus Supplement and accompanying prospectus thereto, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus Supplement and accompanying
prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus Supplement and accompanying prospectus and any future amendments or supplements thereto.
As of the date of this prospectus supplement, we are subject to General Instruction I.B.6 of Form S-3, which limits the
amounts that we may sell under the registration statement of which this prospectus supplement and the Prior Prospectus Supplement are a part. After giving effect to these limitations and the current public float of our common stock, we currently may
offer and sell shares of our common stock having an aggregate offering price of up to $7,023,693 under the Sales Agreement. If our public float increases such that we may sell additional amounts under the Sales Agreement and the registration
statement of which this prospectus supplement and the Prior Prospectus Supplement are a part, we will file another prospectus supplement prior to making additional sales.
We have previously sold $719,351 of common stock pursuant to the Sales Agreement.
Our common stock is listed on the NYSE American under the symbol “PZG.” The last reported sale price of our common stock on May 14, 2024 was
$0.61 per share. As of May 14, 2024, the aggregate market value of our outstanding common stock held by non-affiliates, or public float, was approximately $30,593,938 based on 63,699,496 shares of
outstanding common stock, of which 50,153,997 were held by non-affiliates, and a per share price of $0.61, the closing sale price of our common stock on the NYSE American on May 14, 2024. We have sold
$3,174,286 of securities, represented by 10,987,803 shares of common stock, pursuant to General Instruction I.B.6 of Form S-3 during the 12-month period that ends on and
includes the date of this prospectus supplement. In no event will we sell securities in public primary offerings on Form S-3 with a value exceeding more than one-third
of our public float in any 12 calendar month period so long as our public float remains below $75 million.
Investing in our common stock
involves risks. See the “Risk Factors” on page S-7 of the Prior Prospectus Supplement and under similar headings in other documents that are incorporated by reference into this prospectus supplement
and the Prior Prospectus Supplement for a discussion of the factors you should consider before making a decision to invest in our common stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus supplement or the Prior Prospectus Supplement and accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is May 16, 2024.
